Modelling the potential financial impacts of expanding access to immune checkpoint inhibitors as monotherapy for treating advanced non-small cell lung cancer
This publication was made available as open access through WHO funding provided by two projects: the Universal Health Coverage Partnership (Award 74812, the European Union, the Grand Duchy of Luxembourg, Irish Aid, the Government of Japan, the French Ministry for Europe and Foreign Affairs, the United Kingdom's Foreign, Commonwealth & Development Office, the Government of Belgium, the Government of Canada, and the Government of Germany) and the Increasing Global Equitable Access to Health Products & Health Technologies project (Award 72913, the Government of Belgium).
Authors
- Filip Meheus (ORCID: https://orcid.org/0000-0003-1999-6090)
- Zeba Aziz (ORCID: https://orcid.org/0000-0001-5032-4503)
- Lorenzo Moja (ORCID: https://orcid.org/0000-0001-6680-6507)
- Dario Trapani (ORCID: https://orcid.org/0000-0003-1672-9560)
- Elisabeth G.E. de Vries (ORCID: https://orcid.org/0000-0002-8949-7425)
- André Ilbawi (ORCID: https://orcid.org/0000-0002-4751-6595)
- Manju Sengar
- Kiu Tay-Teo
Institutions
- University Medical Center Groningen (NL)
- University of Groningen (NL)
- University of Milan (IT)
- Rashid Latif Medical College (PK)
- Tata Memorial Hospital (IN)
- World Health Organization (CH)
- European Institute of Oncology (IT)
Publication Details
- Journal
- EClinicalMedicine
- Published
- 2025-05-24
- DOI
- https://doi.org/10.1016/j.eclinm.2025.103261
- Citations
- 6
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 6.27
Funders
- Irish Aid
- Government of Canada
- European Commission
- Ministère de l'Europe et des Affaires Étrangères
- European Society for Medical Oncology